The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company ...

BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments. For each CureVac share they own, investors will get ...

BioNTech is working on this program with OncoC4, a privately held oncology-focused clinical-stage biotech company. BioNTech plans on kicking off more late-stage clinical trials through the next year.

MAINZ, Germany, November 4, 2024-- BioNTech SE today reported financial results for the three and nine months ended September 30, 2024 and provided an update on its corporate progress. Ugur Sahin ...

Moderna claims Pfizer-BioNTech’s COVID vaccine infringes on patents it filed between 2010 and 2016 covering its mRNA technology.

Before new versions of the Omicron strain took hold in the U.S., Pfizer Inc. and BioNTech SE had begun tinkering with their widely used Covid-19 vaccine. In May, researchers tracking how ...

Moderna is suing its chief competitor in the COVID-19 vaccine space, alleging that Pfizer and BioNTech stole key technology used in the development of that group's inoculation.Both Moderna and the ...